On the stock market since 2017, it operates in the world of health and science. It has 972 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 89% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $260.6M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 23 buys and 5 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $2.93 — 70% above today’s price.
A loss of $81.3M against $260.6M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, TRSSF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TRSSF is a high-risk stock — not yet profitable, and its future rides on its product catching on.